China Healthcare Weekly (Dec.31)-1st State-Level Device Policy,TCM Guideline,TCM Rally Unsustainable
This insight analyzed the 14th Five-Year Plan for medical device industry, the new guideline on medical insurance to support TCM development, and...
467 Views
Hong Kong Buybacks: Wuxi Biologics Spent HKD2.8bn
We highlight the top 3 companies that repurchased the most shares in HK were Wuxi Biologics (2269 HK), Cspc Pharmaceutical (1093 HK), Ping An H&T...
577 Views
Hong Kong Buybacks: Wuxi Biologics Utilized 50% of Repurchase Mandate
We highlight the top 3 companies that repurchased the most shares in HK were Wuxi Biologics (2269 HK), Ping An H&T (1833 HK), Xinyi Glass (868 HK)...
561 Views
The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)
The article analyzed CXO plunge last week, the potential impact, the investment logic, the outlook on CXO and biotech, the scenarios when are...
394 Views
Hong Kong Connect Flows: Chinese Buying Tsingtao Brewery
We highlight Hong Kong Connect inflows into Tencent (700 HK), Meituan (3690 HK), Tsingtao Brewery (168 HK), and outflows from Wuxi Biologics (2269...
400 Views